SCHEDULE: Vedanta, Saxena Update Reviva Holdings Stake

Vedanta Partners and Parag Saxena filed an Amendment No. 11 to their Schedule 13D, updating their beneficial ownership in Reviva Pharmaceuticals Holdings, Inc.

Summary

• Vedanta Partners, LLC beneficially owns 5,367,069 shares of Reviva Pharmaceuticals Holdings, Inc. common stock, representing 5.4% of the outstanding class.
• Parag Saxena beneficially owns 6,259,806 shares of Reviva Pharmaceuticals Holdings, Inc. common stock, representing 6.2% of the outstanding class.
• The beneficial ownership percentages are based on 96,337,119 outstanding shares of common stock as of September 22, 2025.
• Vedanta Partners' holdings include common stock, warrants, and pre-funded warrants held by Vedanta Associates-R, Beta Operators Fund, Vedanta Associates, and Vedanta R2 Partners.
• Mr. Saxena's holdings include directly held common stock, shares held by the Vedanta entities, warrants, pre-funded warrants, and 21,400 fully vested options.
• Certain warrants held by Vedanta Associates-R and Beta Operators contain an issuance limitation, prohibiting exercise if it would result in beneficial ownership exceeding 4.99% of the outstanding common stock.

Sentiment

Score: 5

Explanation: This filing is a factual update on beneficial ownership and does not contain information that would inherently convey positive or negative sentiment regarding the company's performance or prospects.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Provides transparency to shareholders and the market regarding significant ownership stakes in Reviva Pharmaceuticals Holdings, Inc.

Key Dates

Keywords

Reviva Pharmaceuticals, Vedanta Partners, Parag Saxena, Schedule 13D, beneficial ownership, common stock, warrants, pre-funded warrants